Literature DB >> 6863097

Effect of beta-adrenergic blockade on hyperventilation and exercise tolerance in emphysema.

R J Butland, J A Pang, D M Geddes.   

Abstract

Ventilation, heart rate, and arterial blood gas tensions were measured at rest and during incremental exercise in 10 patients with emphysema after intravenous placebo or 7 mg metoprolol. Metoprolol reduced heart rate by 14% (P less than 0.001) and ventilation by 11% (P less than 0.01), but there was no significant difference in arterial O2 or CO2 tension (Pao2 and PaCO2, respectively). Metoprolol increased the time to exhaustion on a cycle ergometer (P less than 0.05) but did not improve the 12-min walking distance. A double-blind randomized crossover comparison of 4 wk treatment with atenolol (100 mg/day), metoprolol (100 mg/day), or matched placebo was performed in 12 patients with emphysema. Both beta-adrenoceptor antagonists reduced resting heart rate by 33% (P less than 0.001) and resting minute ventilation by 11% (P less than 0.025). There was no change in resting or exercise Pao2 or Paco2. During steady-state exercise on a cycle ergometer, atenolol and metoprolol reduced ventilation by 14 and 4%, respectively. This was accompanied by 11 and 5% reductions in O2 consumption (P less than 0.05) and 13 and 6% falls in CO2 production (P less than 0.05). There were no significant changes in tests of exercise tolerance, but forced expiratory volume in 1 s and forced vital capacity were reduced during beta 1-adrenergic blockade. beta 1-Blocking drugs reduce hyperventilation in emphysema by reducing pulmonary gas exchange without a change in arterial blood gas tensions. Increased airflow obstruction prevents this reduction being of therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6863097     DOI: 10.1152/jappl.1983.54.5.1368

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  4 in total

1.  Effects of beta-adrenoceptor blockade on exercise performance and respiratory response in healthy, physically untrained humans.

Authors:  B Violante; G Buccheri; V Brusasco
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 2.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S Salpeter; T Ormiston; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 3.  Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.

Authors:  Khaled Albouaini; Mohammed Andron; Albert Alahmar; Mohaned Egred
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 4.  Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.

Authors:  Claudia Gulea; Rosita Zakeri; Vanessa Alderman; Alexander Morgan; Jack Ross; Jennifer K Quint
Journal:  Respir Res       Date:  2021-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.